Health Care & Life Sciences » Pharmaceuticals | Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.82
Market Cap
$2.54 M
Shares Outstanding
36.35 M
Public Float
35.19 M

Profile

Address
550 Sylvan Avenue
Englewood Cliffs New Jersey 07632
United States
Employees -
Website http://www.immunepharma.com
Updated 09/14/2018
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases.

Financials

View All

Anthony S. Fiorino
CEO, COO, Chief Medical Officer & Director
Daniel Kazado
Director